What is Glutathione?

A small three-amino-acid molecule the body makes, mostly in the liver, that cells use in their own antioxidant chemistry.

At a glance

What it is
A small three-amino-acid molecule the body makes, mostly in the liver, that cells use in their own antioxidant chemistry.
Also called
L-glutathione · GSH · reduced glutathione
US status
503A basis to verifyPharmacies compound it, but FDA has not confirmed the basis a 503A pharmacy relies on.
Evidence
C: Small or uncontrolled human dataSmall, short or uncontrolled human studies, for the injected "antioxidant / detox / skin / energy" uses that programs sell; in 2022 the FDA found "insufficient evidence" for all 24 uses it reviewed.
Safety signal
Known serious riskProduct-quality-driven serious reactions documented by FDATheoretical risk named by FDA or reviewsAnaphylaxis, liver toxicity, IVNo data (unknown ≠ safe)Long-term injected use, pregnancy

Status checked Nov 16, 2026 · To verify

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Randomized controlled trials54Measured: blood glutathione during use and 1 month after stopping, in 54 healthy adults taking it by mouth for 6 months in a randomized trial (Richie 2015).26
Randomized controlled trials60Measured: melanin index at 6 skin sites against placebo, in 60 people taking it by mouth for 4 weeks in a randomized, double-blind trial (Arjinpathana 2012).40
Randomized controlled trials21Measured: Parkinson's scores (UPDRS) in 21 people with Parkinson's disease given IV glutathione or placebo for 4 weeks, in a randomized, double-blind pilot (Hauser 2009).25
Randomized controlled trialsNot statedMeasured: self-rated skin tone and adverse events in a small placebo-controlled trial of IV glutathione for skin lightening over 6 weeks, as reported in a review (Zubair 2017).22

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Controlled studies40Measured: oxidative-stress markers and glutathione status in 40 people (39 completed) taking it by mouth for 4 weeks (Allen 2011).38
Controlled studiesNot statedMeasured: melanin index, wrinkles and skin elasticity in healthy women taking it by mouth for 12 weeks; the abstract does not give their number (Weschawalit 2017).41
Open-label studies7Measured: plasma glutathione over 270 minutes in 7 people after taking it once by mouth (Witschi 1992).37
Open-label studies12Measured: blood glutathione in 12 people taking liposomal glutathione by mouth for 1 month, in a study funded by a supplement maker (Sinha 2018).39
ReviewsNot statedA systematic review of topical glutathione in dermatology found 5 small trials and rated the evidence low (Khanna 2025).23
Reviews285Measured: lung function, in a 2019 Cochrane review of antioxidants in cystic fibrosis that included 4 inhaled studies with 285 people. Programs do not sell this route.24

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
"Master antioxidant" / supports antioxidant defensesThe body uses glutathione in its own antioxidant chemistry; we found no trial of injections that measured an outcome for this.1113D
Detox / "flushing out heavy metals"We found no human study of this use.11F
Supports liver healthWe found no evaluation of this in the sources we read, and the FDA lists liver toxicity as a risk of IV use.11F
Brightens or lightens skin / reduces aging of skinSmall randomized trials of oral, topical and IV glutathione give mixed findings; in one small IV trial the effect faded by 6 months. The FDA has approved no injectable skin lightener.172223C

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Increased energy / wellbeing / recoveryWe found no human study.11F
Immune supportOne randomized trial of oral glutathione in healthy adults found changes in one immune marker (NK cells) only.26C
Injections raise levels better than oralThe FDA noted that little glutathione is absorbed by mouth and that its IV half-life is short; we found no study that compared the two routes on an outcome.1126C
Raises body glutathione stores (oral)One 6-month randomized trial in 54 people measured higher glutathione levels in blood and cells.26B
Treats Parkinson's / liver disease (seen on seized skin-lightening kits)A pilot randomized trial of IV glutathione in 21 people with Parkinson's disease found no significant difference from placebo.1725C

Safety facts

Reports to the FDA

  • The FDA's adverse event database (FAERS, updated October 28, 2026) holds about 2,158 reports that list glutathione among the products taken; top terms include nausea, abnormal liver function and fever. The reports are not checked, glutathione is often one of several drugs taken, and they do not show cause.16
  • FAERS data to October 28, 2026 hold 2,158 reports that name glutathione among the products taken, 1,728 of them marked serious. By country: China 862, US 666, Italy 61, Japan 48, Canada 45.34
  • Top terms in all FAERS reports to October 28, 2026: nausea 143, off-label use 139, platelet count decreased 130, abnormal liver function 128, fatigue 126, fever 118, anemia 116, headache 111, diarrhea 108, low white cell count 99. Many blood-count terms likely reflect use alongside cancer drugs, since glutathione is often listed with other drugs; the reports do not show cause.34
  • Top terms in the 666 US FAERS reports to October 28, 2026: fatigue 96, headache 81, nausea 68, pain 51, dizziness 46, joint pain 44, shortness of breath 44, insomnia 40, anxiety 38, diarrhea 38.34
  • FAERS reports by year, all countries: 2016, 148; 2017, 96; 2018, 120; 2019, 129; 2020, 183; 2021, 219; 2022, 217; 2023, 186; 2024, 191; 2025, 195; 2026, 183 (to October 28).34
  • FAERS holds 56 US reports for 2026 (to October 28); the top terms are off-label use (6), drug ineffective (5) and headache (5). Fever is not among the top terms, so the cluster of at least 30 patients the FDA described does not show in this public data.34

What the FDA has said

  • At its 2022 advisory committee meeting, the FDA named anaphylaxis, hypersensitivity and liver toxicity with IV use, and bronchoconstriction, wheezing and coughing up blood (hemoptysis) when inhaled. It had no studies of long-term IV use, and raised a possible concern about sun-induced skin cancer with skin lightening.11
  • The FDA warns that unapproved skin-lightening injections may contain unknown ingredients or contaminants, and that unsafe injection practices can spread infection.1718

In studies and reviews

  • Trials and reviews report mild digestive symptoms when taken by mouth, and mild redness when put on the skin. In a small IV skin-lightening trial, liver dysfunction and one anaphylaxis were reported.2223

No data

  • We found no data on pregnancy or breastfeeding, on long-term injected use, or on children. A member of the FDA's advisory committee cited missing reproductive and developmental toxicology data.11

Product quality

  • The FDA has reported high bacterial endotoxin in compounded glutathione injections: 8 patients in 2019 and at least 30 in 2026, some hospitalized. Reactions included fever, chills, low blood pressure, trouble breathing and sepsis-like symptoms.12
  • Victory Medical Center Pharmacy in Austin recalled 3 lots (1980571, 1981940, 1984345) of 200 mg/mL "multi-dose" vials shipped to Texas, Florida and New York, announced and posted on August 5, 2026, with reports of fever, chills, severe headache, nausea, vomiting, fast heart rate, blood pressure changes, body aches and injection-site reactions. Optimal Balance Pharmacy in Houston recalled 1 lot (LG342009076) of 200 mg/mL 30 mL vials shipped to 14 states (AZ, CO, FL, IL, LA, MI, NY, NV, OK, PA, TX, UT, VT, WA), dated August 19 by the company and posted by the FDA on August 20, 2026, with reports of fever, chills, severe headache, nausea, vomiting, pain and allergic-type symptoms. Both said "pharmacy testing identified elevated bacterial endotoxin levels".34
  • The FDA named the root cause: powder of dietary supplement grade used to make injections. It says such ingredients are "not suitable for making injectable drugs".2
  • In its notice of August 27, 2026, the FDA said the glutathione was given by IV, alone or with other ingredients, and compounded by different pharmacies that all got lot #229536 from Medisca Inc., labeled dietary supplement grade. Reactions included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, and some patients were hospitalized; Medisca told the FDA on August 20, 2026 that it had warned its US customers, and the FDA "continues to receive reports" and is investigating.2

Compounded glutathione is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Requires a prescription from a licensed prescriber after an individual evaluation (a 503A pharmacy needs a prescription for each patient)5Legal
  • Names the pharmacy that fills it and says whether it is a 503A pharmacy or a 503B outsourcing facility527282930Good practice
  • Uses a pharmacy licensed in your state5Legal
  • Says that compounded glutathione is not FDA-approved21730Good practice
  • Uses pharmaceutical-grade glutathione, not dietary supplement grade, from a manufacturer named on the certificate of analysis (COA)12Good practice
  • Tests each lot for sterility, endotoxin (USP chapter 85), potency and pH, and can show a COA on request122830Good practice
  • Tracks lots, has a recall process, and tells patients how to report a side effect to the FDA (MedWatch)234Good practice
  • Does not sell it as "research use only" or "not for human use"Good practice
  • Does not use "FDA-approved" or "FDA-registered" in a way that suggests the product is approved30Good practice
  • Lists the risks, such as allergic reactions and injection-site reactions, and says what to do if fever or chills follow an injection211Good practice
  • Makes no skin-whitening, disease-treatment or "detox" cure claims17Good practice
  • Shows prices, renewal and cancellation terms clearly27282930Good practice
  • Warns athletes about the WADA rule on IV infusions over 100 mL in 12 hours21Good practice

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
    FDA, 503A nominated bulk substances categories list (updated May 14 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  7. 7.
    FDA, 503B nominated bulk substances categories (Mar 21 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  8. 8.
    FDA, 503B Bulk Drug Substances List (current 05/16/2024)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  9. 9.
  10. 10.
  11. 11.
    FDA, PCAC June 8 2022 meeting transcriptTier 1: regulator or registerfda.govread Nov 16, 2026↩
  12. 12.
    FDA, PCAC June 8 2022 meeting questionsTier 1: regulator or registerfda.govread Nov 16, 2026↩
  13. 13.
  14. 14.
    A4PC, "PCAC recommends glutathione for bulks list" (June 2022)Tier 4: lead onlya4pc.orgread Nov 16, 2026
  15. 15.
    openFDA Drugs@FDA query, active ingredient glutathioneTier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  16. 16.
    openFDA FAERS query, medicinalproduct glutathione (last updated 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  17. 17.
  18. 18.
    AmSpa repost of FDA consumer update on injectable skin lightening (Sept 2015)Tier 3: reference, law firm or pressamericanmedspa.orgread Nov 16, 2026↩
  19. 19.
    USP35–NF30 "Glutathione" monograph (mirror)Tier 3: reference, law firm or pressdrugfuture.comread Nov 16, 2026↩
  20. 20.
    APC brief, Dietary Supplement Monograph (May 17 2021)Tier 3: reference, law firm or pressold.a4pc.orgread Nov 16, 2026↩
  21. 21.
    USADA, "IV Infusions: Explanatory Note" (modified Jul 14 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
  22. 22.
    Alzahrani et al., "Glutathione supplementation for skin lightening: narrative review", Cureus 2025Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
  23. 23.
    Khanna et al., "Systematic review of topical glutathione in dermatology", JCAD 2025Tier 2: peer-reviewed or trial registryjcadonline.comread Nov 16, 2026↩
  24. 24.
    Cochrane: Ciofu et al., "Antioxidant supplementation for lung disease in cystic fibrosis" (2019)Tier 2: peer-reviewed or trial registrycochrane.orgread Nov 16, 2026↩
  25. 25.
  26. 26.
    Richie et al., "RCT of oral glutathione supplementation on body stores", Eur J Nutr 2015Tier 2: peer-reviewed or trial registrypure.psu.eduread Nov 16, 2026↩
  27. 27.
    Heally, glutathione injections pageTier 4: lead onlygetheally.comread Nov 16, 2026↩
  28. 28.
    Invigor Medical, buy glutathione pageTier 4: lead onlytryinvigor.comread Nov 16, 2026↩
  29. 29.
    Wisp, glutathione injections pageTier 4: lead onlyhellowisp.comread Nov 16, 2026↩
  30. 30.
    Eden, glutathione treatment pageTier 4: lead onlyeden.healthread Nov 16, 2026↩
  31. 31.
    Eden press release, PR Newswire (May 20 2025)Tier 4: lead onlyprnewswire.comread Nov 16, 2026
  32. 32.
    TrimRx blog, "Best Glutathione Injection Providers in 2026"Tier 4: lead onlytrimrx.comread Nov 16, 2026
  33. 33.
    NutraIngredients-USA, Kyowa Hakko GRAS self-affirmation for Setria (2018)Tier 4: lead onlynutraingredients-usa.comread Nov 16, 2026↩
  34. 34.
  35. 35.
    ClinicalTrials.gov API v2, studies with glutathione as an intervention (277 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
  36. 36.
    PubMed eutils counts for glutathione (total, humans, animals only, RCTs)Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
    DEA Diversion Control, Controlled Substances – Alphabetical Order (12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  46. 46.
    FDA warning-letter database, full-text search "glutathione"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  47. 47.
  48. 48.
    FDA warning letter, Staska Pharmaceuticals Inc., WL 699291 (May 5 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  49. 49.
    FDA warning letter, GenoGenix LLC, WL 718739 (Jan 20 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  50. 50.
    FDA warning letter, ProRx LLC, WL 723704 (Apr 7 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.